Orthopedic Surgical Treatment of Patients with Tumor-induced Osteomalacia Located in the Hip Bones: A Retrospective Analysis of 10 Years in a Single Center

Abstract

Objective: The orthopedic surgical treatment strategies for patients with tumor-induced osteomalacia (TIO) require improvement, especially for patients where the causative tumors are located in surgically challenging areas, requiring a greater degree of in-depth investigation. This work aims to summarize and investigate clinical features and orthopedic surgical treatment effects of patients with tumor-induced osteomalacia (TIO), whose causative tumors are located in the hip bones.

Methods: A retrospective analysis was conducted on the clinical data of all patients diagnosed with culprit tumors located in the hip bones who underwent surgical treatment at the orthopedic bone and soft tissue tumor sub-professional group of Peking Union Medical College Hospital from January 2013 to January 2023. This retrospective study summarized the clinical data, preoperative laboratory test results, imaging findings, surgery-related data, perioperative changes in blood phosphorus levels, and postoperative follow-up data of all patients who met the inclusion criteria. Normally distributed data are presented as mean and standard deviation, while non-normally distributed data are shown as the means and 25th and 75th interquartile ranges.

Results: The clinical diagnostic criteria for TIO were met by all 16 patients, as confirmed by pathology after surgery. Among the 16 patients, we obtained varying degrees of bone pain and limited mobility (16/16), often accompanied by difficulties in sitting up, walking, and fatigue. An estimated 62.5% (10/16) of patients had significantly shorter heights during the disease stages. All 16 patients underwent surgical treatment for tumors in the hip bones, totaling 21 surgeries. In the pathogenic tumor, there were 16 cases of skeletal involvement and none of pure soft tissue involvement. Out of the 16 patients, 13 cases had a gradual increase in blood phosphorus levels following the latest orthopedic surgery, which was followed up for 12 months to 10 years. Due to unresolved conditions after the original surgery, four patients received reoperation intervention. Two cases of refractory TIO did not improve in their disease course.

Conclusion: In summary, the location of the causative tumor in the hip bone is hidden and diverse, and there is no defined orthopedic surgical intervention method for this case in clinical practice. For patients with TIO where the tumors are located in the hip bones, surgical treatment is difficult and the risk of postoperative recurrence is high. Careful identification of the tumor edge using precise preoperative positioning and qualitative diagnosis is crucial to ensure adequate boundaries for surgical resection to reduce the likelihood of disease recurrence and improve prognosis.

Keywords

Orthopedic surgery / Tumor-induced osteomalacia / Treatment strategy / Hip bone

References

[1] Feng J, Jiang Y, Wang O, Li M, Xing X, Huo L, et al. The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr J. 2017; 64(7): 675–683.

[2] Jiang Y, Xia WB, Xing XP, Silva BC, Li M, Wang O, et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res. 2012; 27(9): 1967–1975.

[3] Bosman A, Palermo A, Vanderhulst J, De Beur SMJ, Fukumoto S, Minisola S, et al. Tumor-induced osteomalacia: a systematic clinical review of 895 cases. Calcif Tissue Int. 2022; 111(4): 367–379.

[4] Liu Y, He H, Zhang C, Zeng H, Tong X, Liu Q. Phosphaturic mesenchymal tumors: rethinking the clinical diagnosis and surgical treatment. J Clin Med. 2022; 12(1): 252.

[5] Minisola S, Fukumoto S, Xia W, Corsi A, Colangelo L, Scillitani A, et al. Tumor-induced osteomalacia: a comprehensive review. Endocr Rev. 2023; 44(2): 323–353.

[6] McCance RA. Osteomalacia with Looser’s nodes (Milkman’s syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947; 16(1): 33–46.

[7] Rendina D, Abate V, Cacace G, D’Elia L, De Filippo G, Del Vecchio S, et al. Tumor-induced osteomalacia: a systematic review and individual patient’s data analysis. J Clin Endocrinol Metab. 2022; 107(8): e3428–e3436.

[8] Dahir K, Zanchetta MB, Stanciu I, Robinson C, Lee JY, Dhaliwal R, et al. Diagnosis and management of tumor-induced osteomalacia: perspectives from clinical experience. J Endocr Soc. 2021; 5(9): bvab099.

[9] Jiang Y, Li X, Huo L, Liu Y, Lyu W, Zhou L, et al. Consensus on clinical management of tumor-induced osteomalacia. Chin Med J. 2021; 134(11): 1264–1266.

[10] Liu S, Zhou X, Liu Y, Zhang J, Xia W. Preoperative evaluation and orthopedic surgical strategies for tumor-induced osteomalacia. J Bone Oncol. 2024; 45: 100600.

[11] Wang H, Zhong D, Liu Y, Jiang Y, Qiu G, Weng X, et al. Surgical treatments of tumor-induced osteomalacia lesions in long bones: seventeen cases with more than one year of follow-up. J Bone Jt Surg Am. 2015; 97(13): 1084–1094.

[12] Sun ZJ, Jin J, Qiu GX, Gao P, Liu Y. Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors. BMC Musculoskelet Disord. 2015; 16: 43.

[13] Zhou X, Liu S, Song A, Huo Z, Wang Y, Liu Y. Successful and effective treatment of oncogenic osteomalacia with bone cement. Pol Arch Intern Med. 2020; 130(4): 332–334.

[14] Hou G, Zhang Y, Liu Y, Wang P, Xia W, Xing X, et al. Head-to-head comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in patients with tumor-induced osteomalacia: a prospective study. Front Oncol. 2022; 12: 811209.

[15] Wang P, Zhang S, Huo L, Jing H, Li F. Prognostic value of positive presurgical FDG PET/CT in the evaluation of tumor-induced osteomalacia. Clin Nucl Med. 2021; 46(3): 214–219.

[16] Jiang Y, Hou G, Cheng W. Performance of 68Ga-DOTA-SST PET/CT, octreoscan SPECT/CT and 18F-FDG PET/CT in the detection of culprit tumors causing osteomalacia: a meta-analysis. Nucl Med Commun. 2020; 41(4): 370–376.

[17] Li X, Jiang Y, Huo L, Wu H, Liu Y, Jin J, et al. Nonremission and recurrent tumor-induced osteomalacia: a retrospective study. J Bone Miner Res. 2020; 35(3): 469–477.

[18] Turin CG, Wilson RJ, Mangone C, Rosenspire K, Berman J, Walker M, et al. A case of tumor-induced osteomalacia: finding the culprit acetabular tumor and successful resection with a novel hip joint-preserving surgery. J Orthop Case Rep. 2021; 11(3): 37–41.

[19] Mishra SK, Kuchay MS, Sen IB, Garg A, Baijal SS, Mithal A. Successful management of tumor-induced osteomalacia with radiofrequency ablation: a case series. JBMR Plus. 2019; 3(7): e10178.

[20] Nakamura K, Ohishi M, Matsunobu T, Nakashima Y, Sakamoto A, Maekawa A, et al. Tumor-induced osteomalacia caused by a massive phosphaturic mesenchymal tumor of the acetabulum: a case report. Mod Rheumatol. 2018; 28(5): 906–910.

[21] Morimoto T, Takenaka S, Hashimoto N, Araki N, Myoui A, Yoshikawa H. Malignant phosphaturic mesenchymal tumor of the pelvis: a report of two cases. Oncol Lett. 2014; 8(1): 67–71.

[22] Baronofsky SI, Kalbhen CL, Demos TC, Sizemore GW. Oncogenic osteomalacia secondary to a hemangiopericytoma of the hip: case report. Can Assoc Radiol J. 1999; 50(1): 26–28.

[23] Liu S, Zhou X, Song A, Huo Z, Wang Y, Xia W, et al. Successful treatment of tumor-induced osteomalacia causing by phosphaturic mesenchymal tumor of the foot. Medicine. 2019; 98(27): e16296.

[24] Zhu W, Ma Q, Bian Y, Zhuang Q, Xia Z, Jin J, et al. Total hip/knee arthroplasty in the treatment of tumor-induced osteomalacia patients: more than 1 year follow-up. PLoS One. 2017; 12(5): e0177835.

[25] Sun J, Zhou X, Xia W, Wu H, Liu S, Wang H, et al. Unusual presentation and surgical treatment of a Phosphaturic mesenchymal tumor in a knee. Front Surg. 2022; 9: 746623.

[26] Zuo QY, Wang H, Li W, Niu XH, Huang YH, Chen J, et al. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients. BMC Musculoskelet Disord. 2017; 18(1): 403.

[27] Liu SZ, Zhou X, Song A, Huo Z, Wang YP, Liu Y. Tumor-induced osteomalacia caused by a phosphaturic mesenchymal tumor of the femur. Chin Med J. 2019; 132(19): 2380–2381.

[28] Ni X, Feng Y, Guan W, Chi Y, Li X, Gong Y, et al. Bone impairment in a large cohort of Chinese patients with tumor-induced osteomalacia assessed by HR-pQCT and TBS. J Bone Miner Res. 2022; 37(3): 454–464.

[29] Verma A, Tewari S, Kannaujia A. Perioperative management of patients with severe hypophosphataemia secondary to oncogenic osteomalacia: our experience and review of literature. Indian J Anaesth. 2017; 61(7): 590–593.

[30] Colangelo L, Pepe J, Nieddu L, Sonato C, Scillitani A, Diacinti D, et al. Long-term bone mineral density changes after surgical cure of patients with tumor-induced osteomalacia. Osteoporos Int. 2020; 31(7): 1383–1387.

[31] Horng JC, Van Eperen E, Tutton S, Singh R, Shaker JL, Wooldridge AN. Persistent phosphaturic mesenchymal tumor causing tumor-induced osteomalacia treated with image-guided ablation. Osteoporos Int. 2021; 32(9): 1895–1898.

[32] Cowan S, Lozano-Calderon SA, Uppot RN, Sajed D, Huang AJ. Successful CT guided cryoablation of phosphaturic mesenchymal tumor in the soft tissues causing tumor-induced osteomalacia: a case report. Skeletal Radiol. 2017; 46(2): 273–277.

[33] Jan de Beur SM, Minisola S, Xia WB, Abrahamsen B, Body JJ, Brandi ML, et al. Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia. J Intern Med. 2023; 293(3): 309–328.

[34] Fukumoto S. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment. J Mol Endocrinol. 2021; 66(2): R57–R65.

[35] Crotti C, Zucchi F, Alfieri C, Caporali R, Varenna M. Long-term use of burosumab for the treatment of tumor-induced osteomalacia. Osteoporos Int. 2023; 34(1): 201–206.

RIGHTS & PERMISSIONS

2024 The Authors. Orthopaedic Surgery published by Chinese Orthopaedic Association and John Wiley & Sons Australia, Ltd.